{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:30:20Z","timestamp":1792287020556,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["FI20\/00090"],"award-info":[{"award-number":["FI20\/00090"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113747","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T23:04:12Z","timestamp":1663974252000},"page":"113747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam"],"prefix":"10.1016","volume":"155","author":[{"given":"Pablo","family":"Zubiaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Figueiredo-Tor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Soria-Chacartegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Novalbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113747_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cn5000056","article-title":"Classics in chemical neuroscience: diazepam (Valium)","volume":"5","author":"Calcaterra","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.113747_bib2","first-page":"1","article-title":"GABA","author":"Jorgensen","year":"2005","journal-title":"WormBook"},{"key":"10.1016\/j.biopha.2022.113747_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1192\/bjp.179.5.390","article-title":"New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder","volume":"179","author":"Nutt","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.biopha.2022.113747_bib4","unstructured":"K. Leung, N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, in: Molecular Imaging and Contrast Agent Database (MICAD), National Center for Biotechnology Information (US), Bethesda (MD), 2004. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK23087\/\u3009 (accessed February 18, 2022)."},{"key":"10.1016\/j.biopha.2022.113747_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/00223980.1990.10543259","article-title":"Diazepam (Valium): its dependency liability","volume":"124","author":"Murray","year":"1990","journal-title":"J. Psychol."},{"key":"10.1016\/j.biopha.2022.113747_bib6","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1073\/pnas.0915139107","article-title":"Inhibitory role for GABA in autoimmune inflammation","volume":"107","author":"Bhat","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.113747_bib7","unstructured":"Benzodiazepines, in: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), 2012. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548298\/\u3009 (accessed February 18, 2022)."},{"key":"10.1016\/j.biopha.2022.113747_bib8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.30.11.1257","article-title":"Stereoselective conjugation of oxazepam by human UDP-Glucuronosyltransferases (UGTs): S -Oxazepam is glucuronidated by UGT2B15, while R -Oxazepam is glucuronidated by UGT2B7 and UGT1A9","volume":"30","author":"Court","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2022.113747_bib9","unstructured":"L. Dean, Diazepam Therapy and CYP2C19 Genotype, in: V.M. Pratt, S.A. Scott, M. Pirmohamed, B. Esquivel, M.S. Kane, B.L. Kattman, A.J. Malheiro (Eds.), Medical Genetics Summaries, National Center for Biotechnology Information (US), Bethesda (MD), 2012. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK379740\/\u3009 (accessed February 19, 2022)."},{"key":"10.1016\/j.biopha.2022.113747_bib10","unstructured":"FDA. Prescribing information for Valium (diazepam) tablets. Available on the Internet. Accessed on 4 March 2022. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/013263s094lbl.pdf\u3009, (n.d.)."},{"key":"10.1016\/j.biopha.2022.113747_bib11","unstructured":"CIMA (AEMPS). November 2021. Ficha t\u00e9cnica DIAZEPAM CINFA 5 MG COMPRIMIDOS EFG. Spain. Available on the Internet. Accessed on 3 March 2022. \u3008https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/80698\/FichaTecnica_80698.html#10-fecha-de-la-revisi-n-del-texto\u3009, (n.d.)."},{"key":"10.1016\/j.biopha.2022.113747_bib12","unstructured":"CPIC. Prioritization of CPIC Guidelines. Available on the Internet: \u3008https:\/\/cpicpgx.org\/prioritization-of-cpic-guidelines\/\u3009. Accessed on 4March 2021., (n.d.)."},{"key":"10.1016\/j.biopha.2022.113747_bib13","doi-asserted-by":"crossref","DOI":"10.2349\/biij.4.1.e5","article-title":"The importance of good clinical practice guidelines and its role in clinical trials","volume":"4","author":"Vijayananthan","year":"2008","journal-title":"Biomed. Imaging Interv. J."},{"key":"10.1016\/j.biopha.2022.113747_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"[Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system]","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Clin."},{"key":"10.1016\/j.biopha.2022.113747_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cpt.1409","article-title":"Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy","volume":"106","author":"Brown","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib22","first-page":"2557","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin\u2010associated musculoskeletal symptoms","author":"Cooper\u2010DeHoff","year":"2022","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib23","unstructured":"Curation of DPWG content into PharmGKB. Available on the Internet: \u3008https:\/\/www.pharmgkb.org\/page\/dpwgMapping#cyp3a4\u3009. Accessed on 24 April 2022., (n.d.)."},{"key":"10.1016\/j.biopha.2022.113747_bib24","unstructured":"The Pharmacogenomics Knowledgebase, Very Important Pharmacogene: NAT2, (n.d.). \u3008https:\/\/www.pharmgkb.org\/vip\/PA166170337\u3009 (accessed May 12, 2022)."},{"key":"10.1016\/j.biopha.2022.113747_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The epidemiology of benzodiazepine misuse: a systematic review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.biopha.2022.113747_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113747_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111087","article-title":"Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers","volume":"133","author":"Zubiaur","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113747_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clpt.2005.08.020","article-title":"CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia","volume":"78","author":"Inomata","year":"2005","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113747_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2012.00318","article-title":"Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine","volume":"3","author":"Lee","year":"2013","journal-title":"Front. Gene."},{"key":"10.1016\/j.biopha.2022.113747_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2022.113747_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187231207779814283","article-title":"Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam","volume":"1","author":"Olivera","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.biopha.2022.113747_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J. Biochem Cell Biol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:16:54Z","timestamp":1781781414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222011362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"alternative-id":["S0753332222011362"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113747","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113747"}}